ZVSA
Closed
Zyversa Therapeutics Inc.
2.51
0.00 (0.00%)
Last Update: 06 Sep 2024 23:00:00
Yesterday: 2.51
Day's Range: 2.51 - 2.765
Send
sign up or login to leave a comment!
When Written:
1.69
ZyVersa Therapeutics Inc. is a clinical-stage biopharmaceutical company that specializes in developing innovative therapies for patients with inflammatory and renal diseases. The company's focus is on developing proprietary drugs that target the underlying causes of these diseases, with a goal of improving patient outcomes and quality of life.
ZyVersa's lead product candidate, VAR 200, is a novel, orally administered small molecule inhibitor of the inflammasome complex. It is currently being evaluated in a Phase 2 clinical trial for the treatment of patients with moderate to severe atopic dermatitis.
The company also has a pipeline of other product candidates, including VAR 300, a potential treatment for diabetic nephropathy, and VAR 400, a potential treatment for lupus nephritis.
ZyVersa was founded in 2015 and is headquartered in Westlake Village, California. The company is led by a team of experienced executives and scientists with a proven track record of developing successful therapies for inflammatory and renal diseases.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
ZyVersa's lead product candidate, VAR 200, is a novel, orally administered small molecule inhibitor of the inflammasome complex. It is currently being evaluated in a Phase 2 clinical trial for the treatment of patients with moderate to severe atopic dermatitis.
The company also has a pipeline of other product candidates, including VAR 300, a potential treatment for diabetic nephropathy, and VAR 400, a potential treatment for lupus nephritis.
ZyVersa was founded in 2015 and is headquartered in Westlake Village, California. The company is led by a team of experienced executives and scientists with a proven track record of developing successful therapies for inflammatory and renal diseases.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!
When Written:
1.69
ZyVersa Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for inflammatory and renal diseases. The company's lead product candidate, VAR 200, is a novel, orally-administered, small molecule inhibitor of pro-inflammatory cytokines that is being developed for the treatment of various inflammatory diseases, including psoriasis, rheumatoid arthritis, and lupus. ZyVersa also has a pipeline of other product candidates, including ZYP-101, which is being developed for the treatment of focal segmental glomerulosclerosis (FSGS) and other renal diseases. The company is headquartered in Westlake Village, California.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!